Featured

Qualcomm 2025 M&A Recap: Big Strides in AI, IoT, and Auto
Feb 3, 2026

The EA Buyout: A $55 Billion Bet on the Future of Gaming, or a Debt-Fueled Mistake?
Feb 2, 2026

J&J’s Big Swing: The Single Pill Acquisition That Shook Biopharma
Nov 19, 2025

The New Corporate Guillotine: How One Email Can End a CEO
Nov 15, 2025

The $5.3 Billion Roller Coaster: How Jana Partners and Travis Kelce Plan to Save Six Flags
Nov 8, 2025

The $2.1 Billion Sleep Deal: Alkermes’s Biggest Gamble Yet
Nov 6, 2025

The $300 Billion Warning: Why Luxury's Summer Collapse Signals Crisis Ahead
Sep 21, 2025

The Congressman Betting Against America: What Tim Moore's TZA Trades Really Signal
Sep 10, 2025

Musk’s $17 Billion Bet: How SpaceX Just Bought Its Way Into America’s Wireless Oligopoly
Sep 9, 2025

Beijing’s Property Gamble: What Investors Are Really Betting On
Aug 31, 2025

Qualcomm 2025 M&A Recap: Big Strides in AI, IoT, and Auto

Yessica Jain
Feb 3, 2026
In a single year, Qualcomm completed six acquisitions across AI and semiconductor infrastructure. The message is clear: as its traditional modem business faces long-term erosion, Qualcomm is racing to transform itself from a communications specialist into a fully integrated AI platform company.

The EA Buyout: A $55 Billion Bet on the Future of Gaming, or a Debt-Fueled Mistake?

Shaurya Vohra
Feb 2, 2026
Leveraged buyouts thrive on predictability. Video games do not. EA’s $55 billion take-private deal forces one of the most creatively volatile industries to operate under one of the most financially rigid ownership structures.

J&J’s Big Swing: The Single Pill Acquisition That Shook Biopharma

Cayden Liu
Nov 19, 2025
Johnson & Johnson dropped $14.6 billion on a company whose value rests almost entirely on one psychiatric drug. Caplyta may be a blockbuster, or it may be the most expensive overreach in biotech since 2022. This is a high-risk, high-premium gamble at a moment when Big Pharma can’t afford missteps.

The New Corporate Guillotine: How One Email Can End a CEO

Shaurya Vohra
Nov 15, 2025
One activist email can now do what used to take a full proxy war: topple a CEO. With record campaigns and the Universal Proxy Card turning every board seat into open combat, corporate governance has become faster, louder, and far more ruthless than ever before.

The $5.3 Billion Roller Coaster: How Jana Partners and Travis Kelce Plan to Save Six Flags

Samuel Regelman
Nov 8, 2025
When a company with $5.3 billion in debt and a 47% stock collapse attracts a hedge fund and an NFL star, it’s not charity, it’s strategy. Jana Partners and Travis Kelce are betting they can turn Six Flags from a sinking relic into a comeback story worth watching.

The $2.1 Billion Sleep Deal: Alkermes’s Biggest Gamble Yet

Yessica Jain
Nov 6, 2025
Alkermes just placed a $2.1 billion bet on sleep with a sleep drug few investors saw coming. Alkermes isn’t just buying Avadel, it’s buying time and maybe the future of mental health medicine.

The $300 Billion Warning: Why Luxury's Summer Collapse Signals Crisis Ahead

Eliazar Marchenko
Sep 21, 2025
LVMH’s sharpest sales drop since 2008 is more than a fashion story. Luxury’s downturn has historically foreshadowed recessions, and today it coincides with weakening confidence, asset stress, and slowing global demand.

The Congressman Betting Against America: What Tim Moore's TZA Trades Really Signal

Eliazar Marchenko
Sep 10, 2025
As Vice Chairman of the Financial Services Committee, Tim Moore helps set the rules for America’s markets. He is also betting millions that those markets, and the small businesses they support, are about to fail.

Musk’s $17 Billion Bet: How SpaceX Just Bought Its Way Into America’s Wireless Oligopoly

Eliazar Marchenko
Sep 9, 2025
Elon Musk just paid $17 billion for spectrum licenses, most experts call worthless, 100 times the going rate. On paper, the deal looks insane. Through Washington’s lens, it’s the smartest move SpaceX has ever made.

Beijing’s Property Gamble: What Investors Are Really Betting On

Eliazar Marchenko
Aug 31, 2025
Beijing can move markets with decrees, but it cannot rewrite the fundamentals dragging the economy down.

Qualcomm 2025 M&A Recap: Big Strides in AI, IoT, and Auto

Yessica Jain
Feb 3, 2026
In a single year, Qualcomm completed six acquisitions across AI and semiconductor infrastructure. The message is clear: as its traditional modem business faces long-term erosion, Qualcomm is racing to transform itself from a communications specialist into a fully integrated AI platform company.

The EA Buyout: A $55 Billion Bet on the Future of Gaming, or a Debt-Fueled Mistake?

Shaurya Vohra
Feb 2, 2026
Leveraged buyouts thrive on predictability. Video games do not. EA’s $55 billion take-private deal forces one of the most creatively volatile industries to operate under one of the most financially rigid ownership structures.

J&J’s Big Swing: The Single Pill Acquisition That Shook Biopharma

Cayden Liu
Nov 19, 2025
Johnson & Johnson dropped $14.6 billion on a company whose value rests almost entirely on one psychiatric drug. Caplyta may be a blockbuster, or it may be the most expensive overreach in biotech since 2022. This is a high-risk, high-premium gamble at a moment when Big Pharma can’t afford missteps.

The New Corporate Guillotine: How One Email Can End a CEO

Shaurya Vohra
Nov 15, 2025
One activist email can now do what used to take a full proxy war: topple a CEO. With record campaigns and the Universal Proxy Card turning every board seat into open combat, corporate governance has become faster, louder, and far more ruthless than ever before.

The $5.3 Billion Roller Coaster: How Jana Partners and Travis Kelce Plan to Save Six Flags

Samuel Regelman
Nov 8, 2025
When a company with $5.3 billion in debt and a 47% stock collapse attracts a hedge fund and an NFL star, it’s not charity, it’s strategy. Jana Partners and Travis Kelce are betting they can turn Six Flags from a sinking relic into a comeback story worth watching.

The $2.1 Billion Sleep Deal: Alkermes’s Biggest Gamble Yet

Yessica Jain
Nov 6, 2025
Alkermes just placed a $2.1 billion bet on sleep with a sleep drug few investors saw coming. Alkermes isn’t just buying Avadel, it’s buying time and maybe the future of mental health medicine.

The $300 Billion Warning: Why Luxury's Summer Collapse Signals Crisis Ahead

Eliazar Marchenko
Sep 21, 2025
LVMH’s sharpest sales drop since 2008 is more than a fashion story. Luxury’s downturn has historically foreshadowed recessions, and today it coincides with weakening confidence, asset stress, and slowing global demand.

The Congressman Betting Against America: What Tim Moore's TZA Trades Really Signal

Eliazar Marchenko
Sep 10, 2025
As Vice Chairman of the Financial Services Committee, Tim Moore helps set the rules for America’s markets. He is also betting millions that those markets, and the small businesses they support, are about to fail.

Musk’s $17 Billion Bet: How SpaceX Just Bought Its Way Into America’s Wireless Oligopoly

Eliazar Marchenko
Sep 9, 2025
Elon Musk just paid $17 billion for spectrum licenses, most experts call worthless, 100 times the going rate. On paper, the deal looks insane. Through Washington’s lens, it’s the smartest move SpaceX has ever made.

Beijing’s Property Gamble: What Investors Are Really Betting On

Eliazar Marchenko
Aug 31, 2025
Beijing can move markets with decrees, but it cannot rewrite the fundamentals dragging the economy down.
Latest — Articles
Latest — Articles
Latest — Articles

Qualcomm 2025 M&A Recap: Big Strides in AI, IoT, and Auto

Yessica Jain
Feb 3, 2026
In a single year, Qualcomm completed six acquisitions across AI and semiconductor infrastructure. The message is clear: as its traditional modem business faces long-term erosion, Qualcomm is racing to transform itself from a communications specialist into a fully integrated AI platform company.

Qualcomm 2025 M&A Recap: Big Strides in AI, IoT, and Auto
Feb 3, 2026

Qualcomm 2025 M&A Recap: Big Strides in AI, IoT, and Auto

Yessica Jain
Feb 3, 2026
In a single year, Qualcomm completed six acquisitions across AI and semiconductor infrastructure. The message is clear: as its traditional modem business faces long-term erosion, Qualcomm is racing to transform itself from a communications specialist into a fully integrated AI platform company.

The EA Buyout: A $55 Billion Bet on the Future of Gaming, or a Debt-Fueled Mistake?

Shaurya Vohra
Feb 2, 2026
Leveraged buyouts thrive on predictability. Video games do not. EA’s $55 billion take-private deal forces one of the most creatively volatile industries to operate under one of the most financially rigid ownership structures.

The EA Buyout: A $55 Billion Bet on the Future of Gaming, or a Debt-Fueled Mistake?
Feb 2, 2026

The EA Buyout: A $55 Billion Bet on the Future of Gaming, or a Debt-Fueled Mistake?

Shaurya Vohra
Feb 2, 2026
Leveraged buyouts thrive on predictability. Video games do not. EA’s $55 billion take-private deal forces one of the most creatively volatile industries to operate under one of the most financially rigid ownership structures.

J&J’s Big Swing: The Single Pill Acquisition That Shook Biopharma

Cayden Liu
Nov 19, 2025
Johnson & Johnson dropped $14.6 billion on a company whose value rests almost entirely on one psychiatric drug. Caplyta may be a blockbuster, or it may be the most expensive overreach in biotech since 2022. This is a high-risk, high-premium gamble at a moment when Big Pharma can’t afford missteps.

J&J’s Big Swing: The Single Pill Acquisition That Shook Biopharma
Nov 19, 2025

J&J’s Big Swing: The Single Pill Acquisition That Shook Biopharma

Cayden Liu
Nov 19, 2025
Johnson & Johnson dropped $14.6 billion on a company whose value rests almost entirely on one psychiatric drug. Caplyta may be a blockbuster, or it may be the most expensive overreach in biotech since 2022. This is a high-risk, high-premium gamble at a moment when Big Pharma can’t afford missteps.

The New Corporate Guillotine: How One Email Can End a CEO

Shaurya Vohra
Nov 15, 2025
One activist email can now do what used to take a full proxy war: topple a CEO. With record campaigns and the Universal Proxy Card turning every board seat into open combat, corporate governance has become faster, louder, and far more ruthless than ever before.

The New Corporate Guillotine: How One Email Can End a CEO
Nov 15, 2025

The New Corporate Guillotine: How One Email Can End a CEO

Shaurya Vohra
Nov 15, 2025
One activist email can now do what used to take a full proxy war: topple a CEO. With record campaigns and the Universal Proxy Card turning every board seat into open combat, corporate governance has become faster, louder, and far more ruthless than ever before.

The $5.3 Billion Roller Coaster: How Jana Partners and Travis Kelce Plan to Save Six Flags

Samuel Regelman
Nov 8, 2025
When a company with $5.3 billion in debt and a 47% stock collapse attracts a hedge fund and an NFL star, it’s not charity, it’s strategy. Jana Partners and Travis Kelce are betting they can turn Six Flags from a sinking relic into a comeback story worth watching.

The $5.3 Billion Roller Coaster: How Jana Partners and Travis Kelce Plan to Save Six Flags
Nov 8, 2025

The $5.3 Billion Roller Coaster: How Jana Partners and Travis Kelce Plan to Save Six Flags

Samuel Regelman
Nov 8, 2025
When a company with $5.3 billion in debt and a 47% stock collapse attracts a hedge fund and an NFL star, it’s not charity, it’s strategy. Jana Partners and Travis Kelce are betting they can turn Six Flags from a sinking relic into a comeback story worth watching.

The $2.1 Billion Sleep Deal: Alkermes’s Biggest Gamble Yet

Yessica Jain
Nov 6, 2025
Alkermes just placed a $2.1 billion bet on sleep with a sleep drug few investors saw coming. Alkermes isn’t just buying Avadel, it’s buying time and maybe the future of mental health medicine.

The $2.1 Billion Sleep Deal: Alkermes’s Biggest Gamble Yet
Nov 6, 2025

The $2.1 Billion Sleep Deal: Alkermes’s Biggest Gamble Yet

Yessica Jain
Nov 6, 2025
Alkermes just placed a $2.1 billion bet on sleep with a sleep drug few investors saw coming. Alkermes isn’t just buying Avadel, it’s buying time and maybe the future of mental health medicine.
Load More
Load More
Load More
